SCHEMBL5350100

SCHEMBL5350100

CC(=O)O[C@H]1OC[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
OGA O60502 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 1/20 0.36
BCHE P06276 1/20 0.35
CA12 O43570 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CHRM2 P08172 2/20 0.34
MEN1 O00255 1/20 0.34
CYP2D6 P10635 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5344597 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL7156149 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL8590554 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL5390328 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL7026542 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL3546297 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL3570498 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL7154349 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL6949988 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL6956183 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003002585-A1 [4-(4-CYANOBENZOYL)PHENYL]GLYCOPYRANOSIDE DERIVATIVES, USE OF SAME AS A MEDICAMENT, PRODUCTION METHOD THEREOF AND COMPOSITIONS LABORATOIRES FOURNIER SA (FR) 2003-01-09 WO claimed
US-20240182507-A1 BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY REATA PHARMACEUTICALS, INC. (US) 2024-06-06 US disclosed
WO-2024051666-A1 DIBENZYLBUTYROLACTONE GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院上海药物研究所 2024-03-14 WO disclosed
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway REATA PHARMACEUTICALS, INC (US) 2023-11-28 US disclosed
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 US disclosed
CN-110291095-B Adenosine analogues and their use in regulating circadian clock 北京生命科学研究所 2023-04-18 CN disclosed
US-20220372058-A1 Substituted Pyrazole Compound, Preparation Method Therefor, Pharmaceutical Composition and Medical Use Thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD (CN) 2022-11-24 US disclosed
US-20210338706-A1 ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-11-04 US disclosed
CN-111848704-A 1, 2-cis alcohol ether xyloside surfactant and preparation method thereof 湘潭大学 2020-10-30 CN disclosed
US-7258902-B2 Chiral 3,4-dihydro-2H-pyran compounds BASF AKTIENGESELLSCHAFT (DE) 2007-08-21 US disclosed
US-6455507-B1 E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES SMITHKLINE BEECHAM CORPORATION 2002-09-24 US disclosed
US-20020094963-A1 BENZIMIDAZOLE DERIVATIVES GLAXO WELLCOME INC. 2002-07-18 US disclosed
US-20010028977-A1 Charging, discharging efficiency; vanadium electrolyte JD HOLDING INC. (KY) 2001-10-11 US disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 US disclosed
EP-0829104-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1998-03-18 EP disclosed
EP-0729648-A4 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LTD (AU) 1997-01-02 EP disclosed
WO-1996035239-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-11-07 WO disclosed
EP-0729648-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-09-04 EP disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 WO disclosed
US-4855417-A Anomeric deacetylation YEDA RESEARCH AND DEVELOPMENT COMPANY LTD (IL) 1989-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094963-A1 BENZIMIDAZOLE DERIVATIVES ZC3HAV1, BRPF3, BRD3 PTPN1 4591/4885POLB 1342/4885GAA 235/4885
US-20220372058-A1 Substituted Pyrazole Compound, Preparation Method Therefor, Pharmaceutical Composition and Medical Use Thereof FARS2, GOT2, HADHB PTPN1 4216/4885POLB 1569/4885GAA 3422/4885
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof FARS2, GOT2, HADHB PTPN1 4216/4885POLB 1569/4885GAA 3422/4885
US-20240182507-A1 BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY HSPA2, HSPA1A, HSP90AB1 PTPN1 3873/4885POLB 2532/4885GAA 245/4885
US-20210338706-A1 ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK PER2, CRY1, ADORA2A PTPN1 2165/4885POLB 1466/4885GAA 4788/4885
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway HSPA2, HSP90AB2P, HSF1 PTPN1 4482/4885POLB 3229/4885GAA 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.